September 22, 2014 2:45 AM ET

Pharmaceuticals

Company Overview of Atherogenics Inc.

Company Overview

On June 22, 2009, Atherogenics Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. AtheroGenics, Inc. focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of chronic inflammatory diseases, including diabetes and coronary heart diseases. The company was founded 1993 and is based in Alpharetta, Georgia.

8995 Westside Parkway

Alpharetta, GA 30009

United States

Founded in 1993

Phone:

678-336-2500

Fax:

678-336-2501

Key Executives for Atherogenics Inc.

Atherogenics Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Aquavit Pharmaceuticals, Inc. United States
Pharmacy Creations, LLC United States
CMP Pharma, Inc. United States
Pharm Ops, Inc. United States
KAI Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Atherogenics Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.